Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to Cart failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from wishlist failed.
Please try again later
Adding to library failed
Please try again
Follow podcast failed
Please try again
Unfollow podcast failed
Please try again
Antibody-Drug Conjugates for Ovarian Cancer — An Interview with Dr Kathleen N Moore
-
Narrated by:
-
By:
Featuring an interview with Dr Kathleen N Moore, including the following topics:
- Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00)
- Comparing toxicities of conventional chemotherapy and ADCs (6:26)
- Potential of ADCs as maintenance therapy for ovarian cancer (11:35)
- Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10)
- Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46)
- Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22)
- Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57)
CME information and select publications
No reviews yet